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The introduction of new therapies into clinical practice raises
a number of problems, both ethical and scientific. Patients
accept, and clinicians administer, experimental treatments in
the hope of therapeutic benefit. However, retrospective
analyses indicate that the chances of achieving this aim are
slim. For example, data from 187 phase I studies on 54 drugs
revealed an objective response rate ofonly 4.2% (Estey et al.,
1986). Set against the limited potential for therapeutic benefit
in a phase I study is the likelihood of toxicity, the aims of a
phase I study including the definition of the maximum
tolerated dose (MTD) and the detailing of adverse side effects
(Von Hoff et al., EORTC New Drug Development Commit-
tee, 1985). Thus it falls upon all those involved to ensure that
phase I studies enrol the minimum number of patients and
that the maximum possible amount of information is derived
from them.
To allow the MTD of a new drug to be defined with
reasonable safety phase I studies involve dose escalation.
However, this introduces an additional complication. Patients
treated at the lower end of the dose escalation strategy are
unlikely to receive even a potentially therapeutic dose since
most cytotoxic drugs are only active at or near the MTD.
The need to initiate phase I studies at what is predicted to be
a non-toxic dose is a reflection of the disparity between the
MTD of cytotoxic drugs in experimental animals and their
MTD in patients. If the MTD was the same in patients and
experimental animals, in every case, dose escalation strategies
would not be required and all patients could be treated
directly at the highest dose that could be safely given. Ret-
rospective analyses of results with 64 cytotoxic drugs shows
that, with only a few exceptions, the ratio of the MTD in
humans and, for example, the LDIo in mice falls within the
range 0.1-10 (Freireich et al., 1986; Homan, 1972; Gold-
smith et al., 1975; Penta et al., 1979; Rozencweig et al., 1981;
Grieshaber & Marsoni, 1986; Collins et al., 1986). The lower
value of 0.1 is the reason why most phase I studies are
started at one tenth the mouse LDIo, the LD1o being chosen
as a more quantifiable end-point in mice than the MTD.
Data from other species do not improve the quantitative
predicability of preclinical toxicology and hence one-tenth
the mouse LDIo is currently the bench mark for the calcula-
tion of phase I trial starting doses.
Collins and co-workers at the National Cancer Institute,
USA made a major contribution to the field of experimental
cancer chemotherapy when, in 1986, they analysed the
reasons for the disparity between the MTD of cytotoxic
drugs in patients and their LD1O in mice (Collins et al., 1986).
In so doing they identified two sets of inter-species variables,
i.e. pharmacokinetic and pharmacodynamic. Pharmaco-
dynamic variables relate to target cell sensitivity which may
be influenced by drug uptake, intracellular metabolism,
interaction with target macromolecules and efflux from the
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cell. Pharmacokinetic variables include the whole body
absorption, distribution, metabolism and excretion of the
agent. These pharmacokinetic factors all impinge upon the
levels of active compound, either parent drug or metabolite,
to which the target cell is exposed and their overall effect in
vivo is reflected in the area under the plasma drug concentra-
tion versus time curve (AUC or C x T - concentra-
tion x time).
In an attempt to identify the relative contributions of
pharmacokinetic and pharmacodynamic variables to the dis-
crepancy between human MTD and mouse LDIO doses, Col-
lins et al. (1986) compared the AUC values in mice and
patients for a range of drugs when given at LDIO and MTD
doses, respectively. For certain drugs, the ratios of the AUC
values at the LDIO and MTD were closer to unity than the
ratios of the doses themselves. This implied that for these
compounds the discrepancy between the mouse LD1O and the
human MTD was largely due to pharmacokinetic variables.
A particularly striking example of this was doxorubicin
where the ratio of the MTD to the LDIo was 5 while the
ratio of the AUC values at these doses was 0.8. Noteworthy
exceptions were certain anti-metabolities where, as a class,
cytotoxicity is not simply related to AUC and intracellular
metabolism is usually required for activity.
In their original study, Collins et al. (1986) identified two
potential methods for applying preclinical pharmacokinetic
information in phase I studies. Both methods were aimed at
reducing the number of dose escalation steps and hence the
clinical and patient resources required. The central premise in
both cases was that there might be a closer relationship
between the AUC values at the human MTD and the mouse
LDIO than between the doses themselves. Hence, by measur-
ing the AUC at the phase I starting dose and comparing this
to the AUC at the LDIO in mice, it should be possible to
escalate doses in a manner appropriate to each drug. Thus if
the AUC at the phase I starting dose is close to the mouse
LDIO AUC, escalation should be conservative, while if the
gap is large dose escalation could be more aggressive. Of the
two methods suggested by Collins et al., one involved doub-
ling the dose until the AUC in patients reaches 40% of the
AUC at the LDIO in mice while the other defined the first
dose escalation as being the square root of the ratio of the
AUC at the mouse LD1O to the AUC at the phase I starting
dose in patients. Both escalation strategies are completed
using a Fibonacci scheme. It is important to note that for
both strategies linear pharmacokinetics are a prerequisite. If
a non-linear increase in AUC with dose is suspected, either
from preclinical data or from early clinical results, then
pharmacokinetically guided dose escalation should not be
attempted. In such cases pharmacokinetic monitoring is in
any case essential so that the size ofdose escalation steps can
be attenuated as the non-linear region of pharmacokinetics is
approached.
Similar conclusions to those of Collins and co-workers
were reached by the Pharmacokinetics and Metabolism
Group of the EORTC (EORTC Pharmacokinetics and
Metabolism Group, 1987) when they reviewed their extensive
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experience of phase I studies and associated preclinical and
pharmacokinetic investigations. However, the EORTC PAM
Group highlighted a number of potential pitfalls which must
be considered in performing such retrospective analyses and
in so doing underlined the need to evaluate the concept
prospectively.
A number of groups have now performed either detailed
retrospective analyses (e.g. van Hennick et al., 1987; Kerpel-
Fronius et al., 1988) or have attempted to apply the pro-
posals of Collins et al. and the EORTC PAM Group pro-
spectively (Smith et al., 1988; Frank et al., 1989; Hantel et
al., 1988; Ames & Loprinzi, 1988; Graham et al., 1989;
Foster et al., 1988; Gianni et al., 1989). Although it is still
too early to comment on the overall value of the approach
certain lessons have already been learnt which should help to
focus future studies. The first lesson relates to the simple but
fundamental issue of assay sensitivity. If the drug assay is not
sensitive enough the levels at the phase I starting dose cannot
be measured and hence calculations on the difference between
the mouse LDIo and phase I starting dose AUC cannot be
performed. Problems of assay sensitivity have been
encountered with two compounds; amphethinile (Smith et al.,
1988) and oxantrazole (Frank et al., 1989; Hantel et al.,
1988; Ames & Loprinzi, 1988). The second area where
difficulty has been encountered in the prospective application
of pharmacokinetically guided dose escalation relates to inter
patient variability in pharmacokinetics. Thus in the phase I
study of the anthrapyrazole C1941 the AUC variation at the
phase I starting dose was 3-fold and this precluded the use of
AUC values in dose escalation calculations (Foster et al.,
1988). This problem might have been foreseen since there is
already ample evidence of inter patient pharmacokinetic
variability in the literature. The challenge in such cases is to
identify the cause of the variation and compensate for it
when calculating doses. Carboplatin is a recent example of
how this can be done (Egorin et al., 1984; Calvert et al.,
1990). Finally, the use of AUC values to guide dose escala-
tion runs into further problems when inter species differences
in pharmacokinetics are particularly marked. Thus attempts
by Gianni and co-workers to use pharmacokinetics to guide
dose escalation in the phase I study of 4'-deoxy-4'-iodo-
doxorubicin were frustrated by pronounced inter species
differences in both metabolism (to an active species) and
protein binding (Gianni et al., 1989).
As in any field of scientific endeavour, these problems
should be greeted as opportunities to learn. Initial experience
of attempts to apply preclinical pharmacokinetic information
to phase I studies has identified or emphasised areas of
weakness which in future studies should be addressed more
carefully. Once this is done it should be possible to improve
the efficiency of phase I studies thereby reducing resource
input, both patient and clinical, and providing answers more
rapidly.
Although the use of pharmacokinetic information has been
identified as onepossible approach to improvingphase I studies
with cytotoxic drugs, the challenge for the future is to enhance
the pharmacodynamic component of early clinical trials.
Clinical methods of monitoring pharmacodynamics are now
highly sophisticated and continue to improve in their accuracy
and sensitivity, notable recent advances being the introduction
ofCTandNMRscanning. However,pharmacodynamic studies
at thecellular ormolecular level remain infrequent components
of phase I studies despite the fact that without them no firm
conclusion can be reached as to the utility ofthe target the new
therapy is designed to exploit. For too long such mechanistic
data have been placed in the category ofnon-essential inform-
ation and, if at all, they have only been accrued after the
drug has entered routine clinical use. With the advent of
powerful techniques such as immunological methods of
detecting drug induced damage, flow cytometric determina-
tion of cellular drug effects and the non-invasive measure-
ment of tumour metabolism by NMR spectroscopy, pharma-
codynamic studies at the molecular and cellular level can be
performed in patients. It is particularly important that this
should be done in the phase I trial as this is the first, and
possibly the last, time that the treatment is given to humans
and hence it is critical that the maximum possible amount of
information is derived as quickly as possible.
For the first time incancerchemotherapy it is nowpossible to
study both sides of the pharmacological coin in the clinical
setting. Bythecombinedapplication ofpharamacodynamic and
pharmacokinetic studies in phase I investigations it should be
possible to reduce simultaneously the resources required and
maximise the benefit obtained. In addition, the improved
application ofpharmacokinetic and pharmacodynamic studies
should allow the more rapid and more rational evaluation of
new therapies and this in turn must enhance the prospects for
improved cancer treatment.
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